The National Pharmaceutical Pricing Authority (NPPA) has implemented price caps on 39 essential medicines, as reported by CNBC TV18 and ANI. The government's regulatory agency has slashed prices for drugs used in the treatment of hypertension, diabetes, and heart disease, among other conditions. According to the notification from the Ministry of Chemicals and Fertilisers, manufacturers of formulations or 'new dry' under the DPCO, 2013, shall fix retail prices not exceeding the specified amounts. The notification, issued on July 8, 2026, fixes ceiling retail prices for medicines used in treating diabetes, hypertension, heart disease, infections, eye disorders, respiratory illnesses, pain management, vitamin deficiencies, cancer, and clot-related emergencies. The latest developments include revised retail prices for Calcium and Vitamin D3 Tablets and revisions for Anti-Rabies Immunoglobulin injection, as reported by LatestLY. The revised prices apply to formulations covered under the DPCO, 2013, with manufacturers, importers and marketers directed to implement the revised prices immediately and print updated Maximum Retail Prices (MRP) on product packs along with mandatory declarations.
The regulatory framework allows for continued market entry while maintaining price controls. As reported by CNBC TV18, any other existing manufacturer launching the same new drug within twelve months of the date of publication of this notification in the Official Gazette is permitted to do so at a retail price not exceeding the price specified in the column. This provision ensures competitive pricing while maintaining regulatory oversight. The order has been issued under paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, empowering the NPPA to fix retail prices of new drugs introduced in the market. Retailers have been instructed to clear existing stock carrying older MRPs in accordance with DPCO norms, ensuring smooth transition to the new pricing structure. Under the DPCO, manufacturers are not permitted to charge more than the retail price fixed by the NPPA, except for applicable Goods and Services Tax (GST), where payable. The Department of Pharmaceuticals stated that if a manufacturer or retailer sells a medicine above the NPPA-approved retail price, it may constitute as a violation of the Drugs (Prices Control) Order, 2013, with the NPPA having authority to recover the overcharged amount along with applicable interest from manufacturers.
The price cap affects a comprehensive range of essential medications, including Tenecteplase (TNK-TPA) Injection, which is the costliest medicine notified at ₹60,238.27 per vial. The drug is used to treat acute myocardial infarction, commonly called heart attack and acute ischemic stroke by dissolving harmful blood clots. Domestic firms such as Reliance Life Sciences, Cadila and others also market generic alternatives to the therapy, priced lower than the innovator brand. The notification covers several medicines used to manage cardiovascular disorders, with Amlodipine Bisoprolol Telmisartan Tablets for hypertension treatment priced at ₹14.74 per tablet. Anti-infective medicines such as Amoxicillin + Potassium Clavulanate and Trypsin-Chymotrypsin combinations have also been brought under the latest price notification. Among the least expensive formulations notified are Clobazam Oral Suspension at ₹2.80 per ml, Aspirin Gastro-Resistant + Atorvastatin Capsules at ₹3.67 per capsule, and Torsemide + Spironolactone Tablets at ₹3.71 per tablet. The NPPA has also fixed prices for ophthalmic formulations such as Nepafenac + Moxifloxacin eye solution, Chlorpheniramine + Hydroxypropyl Methylcellulose eye drops, and Netarsudil + Latanoprost ophthalmic solution, with the latter priced at ₹362.57 per ml. The price for Clopidogrel Aspirin Atorvastatin Capsules, used to reduce the risk of heart attack and stroke, was fixed at ₹6.37 per capsule.
The NPPA has provided specific pricing details for recently revised medications. According to the latest notification, Calcium and Vitamin D3 Tablets have been fixed at ₹8.93 per tablet inclusive of Goods & Services Tax (GST). In a separate development, the authority has revised the rates for Anti-Rabies Immunoglobulin Injection to ₹119.48, as reported by ANI. The revision for Anti-Rabies Immunoglobulin injection represents a 6.49% increase from the earlier price of ₹112.19 per ml. The revision for Anti-Rabies Immunoglobulin injection is part of NPPA's periodic review to ensure availability and affordability of critical care medicines. The retail price of Nepafenac Moxifloxacin Ophthalmic Solution, an eye drop used after eye surgery and for the treatment of bacterial eye infections, was fixed at ₹68.64 per ml. The inclusion of Calcium-Vitamin D3, widely prescribed for bone health and deficiency management, and Anti-Rabies Immunoglobulin, used in post-exposure prophylaxis, will directly benefit patients and hospitals. The latest price revisions are part of the government's ongoing efforts to make essential medicines more affordable while preventing excessive pricing in the pharmaceutical market. This move is expected to reduce out-of-pocket healthcare expenses, particularly for people requiring long-term treatment for chronic illnesses such as diabetes, hypertension and cardiovascular diseases.
The NPPA has granted a five-year price cap exemption to Pneubevax 14, India's first 14-valent Pneumococcal Polysaccharide Conjugate Vaccine manufactured by Hyderabad-based Biological E. The authority allowed the vaccine exemption, stating that the formulation met the requirements of Paragraphs 32(i) and 32(ii) of DPCO, 2013, and was covered under a granted patent. Under Paragraphs 32(i) and 32(ii) of the DPCO, 2013, the provisions of the price control order do not apply to a manufacturer producing a new drug patented under the Indian Patent Act, 1970, and not produced elsewhere, if developed through indigenous research and development, for a period of five years from the date of commencement of its commercial production in the country. The authority has asked Biological E to share with it the date of commercial marketing and commercial production of its formulation in India, along with the price to retailer (PTR) and maximum retail price (MRP) fixed by the company. The fixation and revision of ceiling and retail prices is a routine exercise undertaken by the NPPA, which is tasked with enforcing the provisions of the DPCO, regulating both controlled and decontrolled drug prices, and ensuring the affordability of essential medicines.
